Mini kidney organoids deliver maximal drug screening impact

Eryn E Dixon; Shayna T J Bradford; Benjamin D Humphreys

doi:10.1016/j.stem.2022.06.009

Mini kidney organoids deliver maximal drug screening impact

Cell Stem Cell. 2022 Jul 7;29(7):1011-1012. doi: 10.1016/j.stem.2022.06.009.

Authors

Eryn E Dixon¹, Shayna T J Bradford¹, Benjamin D Humphreys²

Affiliations

¹ Division of Nephrology, Department of Medicine, Washington University in St. Louis, St. Louis, MO, USA.
² Division of Nephrology, Department of Medicine, Washington University in St. Louis, St. Louis, MO, USA; Department of Developmental Biology, Washington University in St. Louis, St. Louis, MO, USA. Electronic address: [email protected].

PMID: 35803221
DOI: 10.1016/j.stem.2022.06.009

Abstract

In this issue of Cell Stem Cell, Tran and colleagues develop a platform for differentiating thousands of miniature kidney organoids consisting of one or two nephron-like structures each. They use this platform to identify a potent new inhibitor of cyst growth in organoid models of autosomal-dominant polycystic kidney disease.

Publication types

Comment

MeSH terms

Drug Evaluation, Preclinical
Kidney*
Nephrons
Organoids*